SCHEMBL30130156

SCHEMBL30130156

CCc1ccccc1Cn1c(=O)c2c(c3cccnc31)CCN(Cc1ccccc1)C2

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 1/20 0.49
▸ CRBN Q96SW2 1/20 0.49
▸ CLPP Q16740 9/20 0.47
▸ ENPP2 Q13822 4/20 0.46
▸ DRD2 P14416 1/20 0.45
▸ DRD4 P21917 1/20 0.45
▸ DRD3 P35462 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24915132 1.00 DDB1 (0.49) DDB1CRBNCLPPENPP2DRD2
SCHEMBL24915123 0.96 ENPP2 (0.50) DDB1CRBNCLPPENPP2DRD2
SCHEMBL24915131 0.91 THRB (0.53) DDB1CRBNCLPPENPP2DRD2
SCHEMBL30130044 0.91 THRB (0.53) DDB1CRBNCLPPENPP2DRD2
SCHEMBL24914704 0.91 CLPP (0.50) DDB1CRBNCLPPENPP2DRD2
SCHEMBL24914797 0.91 CLPP (0.50) DDB1CRBNCLPPENPP2DRD2
SCHEMBL24914395 0.91 CLPP (0.55) DDB1CRBNCLPPENPP2DRD2
SCHEMBL24915133 0.90 ENPP2 (0.44) DDB1CRBNCLPPENPP2KDM4E
SCHEMBL24914454 0.90 RXFP1 (0.52) DDB1CRBNCLPPENPP2RXFP1
SCHEMBL30130091 0.90 RXFP1 (0.52) DDB1CRBNCLPPENPP2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327408-A1 COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF CHINA PHARMACEUTICAL UNIVERSITY (CN) 2024-10-03 — — US claimed
CN-115611896-A Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof 中国药科大学 2023-01-17 — — CN claimed
US-20240327408-A1 COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF CHINA PHARMACEUTICAL UNIVERSITY (CN) 2024-10-03 — — US disclosed
CN-115611896-A Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof 中国药科大学 2023-01-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327408-A1 COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF PRCP, TMPRSS15, WEE1 DDB1 3529/4885CRBN 1365/4885CLPP 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback